2. Search Result
Search Result
Results for "

M24

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99829
    Cofetuzumab pelidotin

    PF-06647020; ABBV-647; h6M24-vc0101

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
    Cofetuzumab pelidotin
  • HY-115928
    M24

    		Bcl-2 Family Cancer
    M24 is a Mcl-1 selective inhibitor. M24 exhibits good binding affinity against Mcl-1 with Ki value of 0.33 μM. M24 exhibits good anti-proliferative activity and induce apoptosis in HepG2 cells .
    M24
  • HY-P991175
    Anti-Dectin-1 Antibody (2M24)

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody that targets Dectin-1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Dectin-1 Antibody (2M24)
  • HY-171125
    Maytansine derivative M24

    		Drug-Linker Conjugates for ADC Cancer
    Maytansine derivative M24 is an ADC Drug-Linker Conjugates for ADC that can be used to synthesize ADC REGN5093-M114 .
    Maytansine derivative M24
  • HY-130178
    CL-385319

    		Endogenous Metabolite Infection
    CL-385319 is an N-substituted piperidine compound with inhibitory activity against H5N1 avian influenza A virus infection. CL-385319 exhibited an IC50 of 27.03±2.54 μM against infection of highly pathogenic H5N1 virus in Madin-Darby canine kidney cells (MDCK). CL-385319 had low cytotoxicity with a CC50 of 1.48 mM and was able to inhibit the entry of pseudoviruses carrying H5N1 strains from different sources, but had no inhibitory effect on the entry of VSV-G pseudotyped particles. Pseudoviruses with the M24A mutation in HA1 or the F110S mutation in HA2 were resistant to CL-385319, indicating that these two residues in the cavity region may be critical for the binding of CL-385319 .
    CL-385319
  • HY-W700620
    Hydroxymethyl dasatinib

    		Bcr-Abl Drug Metabolite Apoptosis Src Inflammation/Immunology
    Hydroxymethyl dasatinib (M24), a benzylhydroxy metabolite of Dasatinib (HY-10181), exhibits an IC50 of 46.7nM in K562 CML cells .
    Hydroxymethyl dasatinib
  • HY-171843
    TD-6301

    		mAChR Endocrinology
    TD-6301 is a bladder-selective M2/4 muscarinic receptor antagonist. TD-6301 binds to and blocks M2/4 muscarinic receptors with high selectivity, especially human M2 receptors with strong affinity (Ki = 0.36 nM). TD-6301 inhibits volume-induced bladder contractions (ID50 = 0.075 mg/kg). TD-6301 can be used in the research of overactive bladder .
    TD-6301
  • HY-RS16519
    Gsdmd Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gsdmd Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gsdmd gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gsdmd Mouse Pre-designed siRNA Set A
    Gsdmd Mouse Pre-designed siRNA Set A
  • HY-183739
    CQ31

    		Pyroptosis Caspase Cancer
    CQ31 is a PEPD and XPNPEP1 inhibitor, with an IC50 of 0.67 μM against PEPD and an IC50 of 122 μM against XPNPEP1. CQ31 inhibits the M24B aminopeptidase activity of PEPD and XPNPEP1. CQ31 induces the accumulation of Xaa-Pro-containing peptides, mildly inhibits DPP8/9, and triggers CASP1-dependent pyroptosis via activation of the CARD8 inflammasome and caspase-1. CQ31 can be used in research related to cancers such as acute myeloid leukemia .
    CQ31

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: